A physiological concentration of glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts: Roles of extracellular signal-regulated kinase 1/2 and nuclear factor-κB

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 11, 2011, Pages 739-746

  He, Yan Hua ^a,b   Zhang, Hai Ning ^a   Zhang, Gui Ping ^a   Hou, Ning ^a   Xiao, Qing ^a   Huang, Yue ^a   Wu, Jian Hui ^a   Luo, Miao Shan ^a   Zhang, Gen Shui ^a   Yi, Quan ^a   Chen, Min Shen ^b   Luo, Jian Dong ^a,c  

^a Department of Pharmacology ^*  (China)

^b Guangzhou Research Insititute of Snake Venom   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Extracellular regulated kinases; Fibroblasts; Glucocorticoid; Nuclear factor B; Proliferation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOTENSIN II; CYCLIN D1; CYTOKINE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PYRROLIDINE DITHIOCARBAMATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FIBROBLAST; HEART MUSCLE CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOTENSIN II; ANIMALS; CELL GROWTH PROCESSES; CELLS, CULTURED; CYCLIN D1; HYDROCORTISONE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; MYOFIBROBLASTS; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 80054917317     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05581.x     Document Type: Article

References (56)

1. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: An overview. Heart 2004; 90: 464-70.
2. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109(Suppl. 1): 112-10.
3. Abbate A, Kontos MC, Grizzard JD et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. Cardiol. 2010; 105: 1371-7.
4. Fix C, Bingham K, Carver W. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 2011; 53: 19-28.
5. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 657-87.
6. Irwin MW, Mak S, Mann DL et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999; 99: 1492-8.
7. Yokoyama T, Sekiguchi K, Tanaka T et al. Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts. Am. J. Physiol. 1999; 276: H1968-76.
8. Venkatachalam K, Venkatesan B, Valente AJ et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J. Biol. Chem. 2009; 284: 14414-27.
9. Qi G, Jia L, Li Y et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc. Toxicol. 2011; 11: 157-67.
10. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005; 65: 40-51.
11. Toischer K, Rokita AG, Unsold B. et al. Differential cardiac remodeling in preload versus afterload. Circulation 2010; 122: 993-1003.
12. Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J. Mol. Cell. Cardiol. 2011; 50: 522-33.
13. Heymans S, Hirsch E, Anker SD et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology Eur. J. Heart Fail. 2009; 11: 119-29.
14. Matsumori A. Anti-inflammatory therapy for heart failure. Curr. Opin. Pharmacol. 2008; 4: 175-6.
15. Celis R, Torre-Martinez G, Torre-Amione G. Evidence for activation of immune system in heart failure: Is there a role for anti-inflammatory therapy? Curr. Opin. Cardiol. 2012; 23: 258-64.
16. Kaur K, Dhingra S, Slezak J, Sharma AK, Bajaj A, Singal PK. Biology of TNFalpha and IL-10, and their imbalance in heart failure. Heart Fail. Rev. 2009; 14: 113-23.
17. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 2004; 94: 1543-53.
18. Fernandes D, Guida E, Koutsoubos V et al. Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 1999; 21: 77-88.
19. Grose R, Werner S, Kessler D et al. A role for endogenous glucocorticoids in wound repair. EMBO Rep. 2002; 3: 575-82.
20. Sundberg M, Savola S, Hienola A, Korhonen L, Lindholm D. Glucocorticoid hormones decrease proliferation of embryonic neural stem cells through ubiquitin-mediated degradation of cyclin D1. J. Neurosci. 2006; 26: 5402-10.
21. Toy EP, Lamb T, Azodi M, Roy WJ, Woo HH, Chambers SK. Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells. Breast Cancer Res. Treat. 2011; 129: 411-9.
22. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002; 96: 23-43.
23. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 1998; 102: 274-82.
24. Rabbitt EH, Lavery GG, Walker EA, Cooper MS, Stewart PM, Hewison M. Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: A novel determinant of cell proliferation. FASEB J. 2002; 16: 36-44.
25. Rogatsky I, Trowbridge JM, Garabedian MJ. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol. Cell. Biol. 1997; 17: 3181-93.
26. O'Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-41.
27. Zhang S, Shen Z, Hu G, Liu R, Zhang X. Effects of endogenous glucocorticoids on allergic inflammation and T(H)1/T(H)2 balance in airway allergic disease. Ann. Allergy Asthma Immunol. 2009; 103: 525-34.
28. Tjandra K, Kubes P, Rioux K, Swain MG. Endogenous glucocorticoids inhibit neutrophil recruitment to inflammatory sites in cholestatic rats. Am. J. Physiol. 1996; 270: G821-5.
29. Ruzek MC, Pearce BD, Miller AH, Biron CA. Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. J. Immunol. 1999; 162: 3527-33.
30. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Natl Acad. Sci. USA 1992; 89: 3917-21.
31. Morand EF, Leech M. Hypothalamic-pituitary-adrenal axis regulation of inflammation in rheumatoid arthritis. Immunol. Cell Biol. 2001; 79: 395-9.
32. Olson ER, Shamhart PE, Naugle JE, Meszaros JG. Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase Cdelta and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 2008; 51: 704-11.
33. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol. 2008; 29: 469-78.
34. Zhang Y, Dong C. Regulatory mechanisms of mitogen-activated kinase signaling. Cell. Mol. Life Sci. 2007; 64: 2771-89.
35. Tada K, Okazaki T, Sakon S et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J. Biol. Chem. 2001; 276: 36530-4.
36. Wan F, Lenardo MJ. The nuclear signaling of NF-kappaB: Current knowledge, new insights, and future perspectives. Cell Res. 2009; 20: 24-33.
37. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1995; 88: 2849-60.
38. Suzuki K, Koizumi N, Hirose H, Hokao R, Takemura N, Motoyoshi S. Model of emotional stress in rats. Lab. Anim. Sci. 1998; 48: 353-6.
39. Vachon P, Moreau JP. Serum corticosterone and blood glucose in rats after two jugular vein blood sampling methods: Comparison of the stress response. Contemp. Top. Lab. Anim. Sci. 2001; 40: 22-4.
40. Zhang HY, Sun H. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 2010; 287: 91-7.
41. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): Mechanisms of action and clinical uses. Annu. Rev. Med. 1997; 48: 129-56.
42. Mahajan DK, London SN. Mifepristone (RU486): A review. Fertil. Steril. 1997; 68: 967-76.
43. Hou N, Luo MS, Liu SM. et al. Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor alpha pathway in cultured neonatal rat cardiomyocytes. Clin. Exp. Pharmacol. Physiol. 2010; 37: 1087-95.
44. Westermann D, Lindner D, Kasner M. et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 2010; 4: 44-52.
45. Saito S, Matsumiya G, Sakaguchi T. et al. Cardiac fibrosis and cellular hypertrophy decrease the degree of reverse remodeling and improvement in cardiac function during left ventricular assist. J. Heart Lung Transplant. 2010; 29: 672-9.
46. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: Interaction with hemodynamic and hormonal factors. Cardiovasc. Res. 1999; 41: 532-43.
47. Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc. Res. 1995; 30: 537-43.
48. Du J, Guan T, Zhang H et al. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem. Biophys. Res. Commun. 2008; 368: 402-7.
49. Wang ZQ, Chen XC, Yang GY, Zhou LF. U0126 prevents ERK pathway phosphorylation and interleukin-1beta mRNA production after cerebral ischemia. Chin. Med. Sci. J. 2004; 19: 270-5.
50. Bird MA, Black D, Lange PA et al. NFkappaB inhibition decreases hepatocyte proliferation but does not alter apoptosis in obstructive jaundice. J. Surg. Res. 2003; 114: 110-7.
51. Tantivejkul K, Loberg RD, Mawocha SC et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J. Cell. Biochem. 2005; 96: 641-52.
52. Adcock IM, Ito K, Barnes PJ. Glucocorticoids: Effects on gene transcription. Proc. Am. Thorac. Soc. 2004; 1: 247-54.
53. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004; 18: 2195-224.
54. Bladh LG, Liden J, Pazirandeh A et al. Identification of target genes involved in the antiproliferative effect of glucocorticoids reveals a role for nuclear factor-(kappa) B repression. Mol. Endocrinol. 2005; 19: 632-43.
55. Liden J, Rafter I, Truss M, Gustafsson JA, Okret S. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. Biochem. Biophys. Res. Commun. 2000; 273: 1008-14.
56. Ravenhall C, Guida E, Harris T, Koutsoubos V, Stewart A. The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle. Br. J. Pharmacol. 2000; 131: 17-28.